At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Daxdilimabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2A, Open Label, Proof of Concept Trial of Daxdilimab for the Treatment of Moderate To Severe Alopecia Areata
In Brief
A Phase 2 clinical trial evaluating Daxdilimab for Alopecia Areata. Completed, enrolled 30 participants across 13 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess the preliminary efficacy, safety, tolerability, PK, and PD of Daxdilimab in participants with moderate to severe AA, with ≥50% and ≤95% total scalp hair loss as defined by the SALT score at Screening and Day 1.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartApr 2022
First PostedMay 2022
Primary CompletionAug 2023
Study CompletionJan 2024
TodayJul 2026
First PostedMay 10, 2022
Enrollment StartApr 27, 2022
Primary CompletionAug 7, 2023
Study CompletionJan 26, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.1 years ago
Interventions
Daxdilimabbiological
Daxdilimab will be administered subcutaneously as two injections for each dose.